HK Grey Market | Metis TechBio Soars 191%; Impact Therapeutics Jumps 41%

Tiger Newspress05-12 16:34

Metis TechBio, one of the "Top Three AI Drug Discovery" companies in Mainland China, soared 191% in Hong Kong’s grey market trading.

Founded in 2020, Metis TechBio focuses on the delivery and application of payloads across a range of biological systems, using artificial intelligence-powered nanotechnology to advance healthcare solutions.

Chinese cancer-drug developer Impact Therapeutics jumped 41% in Hong Kong’s grey market trading.

Founded in 2009, Impact Therapeutics is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment